ClinicalTrials.gg
Active, not recruitingNCT04280718ADHERE+Updated Nov 4, 2026

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

A Phase 2 interventional study of Efgartigimod PH20 SC in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by argenx. Active, not recruiting at 147 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Updated Nov 4, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
229
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Enrollment
4th of 42
229 · median 74
Started
2020
with 2 others
Phase 2
16 of 55
2 open now
Primary completion
2027-04
later than 6 of 24 live
Registered
23rd of 55
by date
Lead sponsor
7 of 55
argenx

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 4th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2020, is one of 16 in phase 2, reaches primary completion later than 6 of the 24 other live ones, and was the 23rd registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the requirements of the trial, provide written (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits) of this trial.
  2. Male or female patient with one of the following options:

    • Have completed the Week-48 visit of Stage B of the ARGX-113-1802 trial and are considered to be eligible for treatment with efgartigimod PH20 SC; or
    • Have deteriorated during Stage B of the ARGX-113-1802 trial and are considered to be eligible for treatment with efgartigimod PH20 SC, or
    • Have been offered the participation in the OLE trial due to early termination of the ARGX-113-1802 trial (because sufficient events for the primary endpoint analysis of the that trial have been reached and it is stopped) and are considered to be eligible for treatment with efgartigimod PH20 SC treatment; or
    • Have completed the Week-48 visit of the previous cycle of the OLE trial and are considered to be eligible to continue with efgartigimod PH20 SC treatment.
  3. Women of who have a negative urine pregnancy test at baseline before IMP administration.
  4. Women of childbearing potential must use an acceptable method of from signing the ICF until the date of the last administration of IMP.

Exclusion criteria

Exclusion Criteria:

  1. Week-48/ED visit in the ARGX-113-1802 trial or the Week-48 visit of the previous OLE participation occurred more than 14 days prior to SD1 of the OLE trial or the start of a new treatment cycle in the OLE trial and more than 21 days since the last dose of IMP.
  2. Pregnant and lactating women and those intending to become pregnant during the trial.
  3. Patients with clinical evidence of other significant serious disease or patients who underwent a recent or have a planned major surgery, or patients who (intend to) use prohibited medications (see protocol) and therapies during the trial, or any other reason which could confound the results of the trial or put the patient at undue risk.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    efgartigimod PH20 SC

    Patients treated with efgartigimod PH20 SC

    Biological: Efgartigimod PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events and serious adverse events

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

Secondary outcomes

  1. Change from baseline over time of the adjusted INCAT score

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  2. Change from baseline over time of the MRC Sum score

    The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome).

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  3. Change from baseline over time of I-RODS disability scores

    Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP. The score ranges from 0 to 100 (higher score, worse outcome).

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  4. Change from baseline over time of mean grip strength

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  5. Change from baseline over time of TUG score

    The Timed Up and Go Test (TUG) is a simple test to assess a person's mobility in which the time expended to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down is measured.

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  6. Percentage of patients without clinical deterioration over time, defined by adjusted INCAT deterioration ≥1 point compared to baseline.

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  7. Percentage of patients with titers of binding antibodies towards efgartigimod and the presence of neutralizing antibodies against efgartigimod.

    Time frame: Up to 51 weeks

  8. Efgartigimod serum concentrations

    Time frame: Up to 51 weeks

  9. Changes from baseline over time of serum IgG levels (total)

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  10. Change from baseline over time in EQ-5D-5L

    EQ-5D-5L questionnaire is a patient-reported outcome measure, ranging 0 to 100 (lower score, worse outcome).

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  11. Change from baseline over time in BPI SF

    The Brief Pain Inventory-Short Form (BPI-SF) is a patient-reported outcome measure to assess pain severity and pain interference

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  12. Change from baseline over time in TSQM-9

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 9-item questionnaire to assess treatment satisfaction in naturalistic study designs, in which there is potential that the administration of the side effects domain of the TSQM would interfere with routine clinical care

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  13. Change from baseline over time in RT-FSS

    The Rasch-Transformed Fatigue Severity Scale (RT-FSS) is a 7-item self-reported questionnaire designed to differentiate fatigue from clinical depression. The participant has to rate from 0 to 3 their level of fatigue on 7 items (low score indicates that the statement is not very appropriate, and high score indicates agreement).

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  14. Change from baseline over time in HADS

    The Hospital Anxiety and Depression Scale (HADS) aims to measure symptoms of anxiety and depression in people with physical health problems. HADS is a 14-item scale with 7 items related to anxiety and 7 to depression

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  15. Percentage of patients performing self-administration over time

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

  16. Percentage of patients with treatment administered by caregiver over time.

    Time frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

07

Study locations

147 sites
  • Investigator site 0010065
    Birmingham, Alabama 35233-2110, United States
  • Investigator site 0010013
    Phoenix, Arizona 85018, United States
  • Investigator site 0010055
    Scottsdale, Arizona 85028, United States
  • Investigator site 0010032
    Carlsbad, California 92011, United States
  • Investigator site 10190
    Pomona, California 91767-2009, United States
  • Investigator site 0010160
    Rancho Mirage, California 92270-4150, United States
  • Investigator site 0010071
    San Francisco, California 94109, United States
  • Investigator site 0010057
    Centennial, Colorado 80112, United States
  • Investigator site 0010072
    Boca Raton, Florida 33487, United States
  • Investigator site 0010144
    Coral Springs, Florida 33067-4640, United States
  • Investigator site 0010023
    Jacksonville, Florida 32209, United States
  • Investigator site 0010068
    Maitland, Florida 32751, United States
  • Investigator site 0010059
    Miami, Florida 33136, United States
  • Investigator site 0010006
    Tampa, Florida 33612, United States
  • Investigator site 0010011
    Iowa City, Iowa 52242, United States
  • Investigator site 0010015
    Fairway, Kansas 66205, United States
  • Investigator site 10147
    Lexington, Kentucky 40536, United States
  • Investigator site 10168
    New York, New York 10016, United States
  • Investigator site 0010003
    Chapel Hill, North Carolina 27517, United States
  • Investigator site 0010064
    Columbus, Ohio 43210, United States
  • Investigator site 0010007
    Philadelphia, Pennsylvania 19107, United States
  • Investigator site 0010047
    Philadelphia, Pennsylvania 19126, United States
  • Investigator Site 0010066
    Austin, Texas 78756, United States
  • Investigator site 0010009
    San Antonio, Texas 78229, United States
  • Investigator site 0010061
    Richmond, Virginia 23298, United States
  • Investigator site 0430007
    Innsbruck, Austria
  • Investigator site 0430008
    Linz, 4021, Austria
  • Investigator site 0430005
    Vienna, 1090, Austria
  • Investigator site 0320016
    Edegem, Belgium
  • Investigator site 0320009
    Leuven, 3000, Belgium
  • Investigator site 320024
    Liège, 4000, Belgium
  • Investigator site 320022
    Woluwe-Saint-Lambert, 1200, Belgium
  • Investigator site 3590007
    Pleven, 5800, Bulgaria
  • Investigator site 3590005
    Sofia, 1113, Bulgaria
  • Investigator site 3590008
    Sofia, 1431, Bulgaria
  • Investigator site 3590006
    Sofia, 1680, Bulgaria
  • Investigator site 0860033
    Beijing, China
  • Investigator site 860041
    Changsha, China
  • Investigator site 0860036
    Chengdu, China
  • Investigator site 860049
    Chifeng, 024000, China
  • Investigator site 0860038
    Fuzhou, China
  • Investigator site 0860050
    Guangzhou, 510120, China
  • Investigator site 0860032
    Guanzhou, China
  • Investigator site 0860045
    Guiyang, China
  • Investigator site 0860035
    Hangzhou, 310003, China
  • Investigator site 0860031
    Jinan, 250012, China
  • Investigator site 0860040
    Nanchang, 33008, China
  • Investigator site 0860043
    Nanjing, China
  • Investigator site 0860028
    Shanghai, China
  • Investigator site 860047
    Shanghai, China
  • Investigator site 0860042
    Tianjin, China
  • Investigator site 0860034
    Wuhan, 430040, China
  • Investigator site 0860029
    Wuhan, 430060, China
  • Investigator site 0860048
    Xi'an, 710038, China
  • Investigator site 0860054
    Xianyang, 712000, China
  • Investigator site 4200010
    Hradec Králové, 500-03, Czechia
  • Investigator site 0450002
    Aarhus, 8200, Denmark
  • Investigator site 0450001
    Copenhagen, 2100, Denmark
  • Investigator site 0450003
    Odense, 5000, Denmark
  • Investigator site 00330034
    Angers, France
  • Investigator site 0330013
    Bordeaux, 33076, France
  • Investigator site 330033
    Clermont-Ferrand, 63003, France
  • Investigator site 0330023
    Le Kremlin-Bicêtre, 94275, France
  • Investigator site 0330024
    Limoges, 87042, France
  • Investigator site 330022
    Nantes, 44093, France
  • Investigator site 0330021
    Nice, 06202, France
  • Investigator site 0330035
    Paris, France
  • Investigator site 0330020
    Strasbourg, 67098, France
  • Investigator site 9950020
    Kutaisi, 4600, Georgia
  • Investigator site 9950004
    Tbilisi, 0112, Georgia
  • Investigator site 9950005
    Tbilisi, 0112, Georgia
  • Investigator site 9950002
    Tbilisi, Georgia
  • Investigator Site 9950003
    Tbilisi, Georgia
  • Investigator site 490044
    Bochum, 44791, Germany
  • Investigator site 0490013
    Cologne, Germany
  • Investigator site 490045
    Essen, 45147, Germany
  • Investigator site 490021
    Göttingen, 37075, Germany
  • Investigator site 0490016
    Kiel, 24105, Germany
  • Investigator site 0490019
    Potsdam, Germany
  • Investigator site 9720004
    Tel Aviv, 6423906, Israel
  • Investigator site 0390022
    Brescia, Italy
  • Investigator site 390029
    Florence, 50139, Italy
  • Investigator site 0390024
    Genova, 16132, Italy
  • Investigator site 390027
    Messina, 98125, Italy
  • Investigator site 0390003
    Milan, 20122, Italy
  • Investigator site 0390026
    Milan, Italy
  • Investigator site 0390023
    Pisa, 56125, Italy
  • Investigator site 0390008
    Roma, 00189, Italy
  • Investigator site 0390042
    Torino, Italy
  • Investigator site 0810035
    Bunkyō City, Japan
  • Investigator site 0810002
    Chiba, Japan
  • Investigator site 0810030
    Fuchū, 183-0042, Japan
  • Investigator site 0810031
    Fukuoka, 812-8582, Japan
  • Investigator site 0810065
    Ginowan, Japan
  • Investigator site 0810066
    Hakodate, Japan
  • Investigator site 0810058
    Hiroshima, Japan
  • Investigator site 0810029
    Kawagoe, Japan
  • Investigator site 0810026
    Kodaira, 187-8551, Japan
  • Investigator site 810061
    Kyoto, 616-8255, Japan
  • Investigator site 0810027
    Mibu, 321-0293, Japan

Showing the first 100 of 147 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Apr 2027, 79 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Feb 21, 2020
StartActual
Sep 18, 2020
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Taiwan)
  • Investigator site 8860013 · Tainan, Taiwan
  • Investigator site 8860017 · Taoyuan, Taiwan
Show 2 removed
  • Investigator site 8860013 · Tainan City, Taiwan
  • Investigator site 8860017 · Taoyuan District, Taiwan
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Taiwan)
    • Investigator site 8860013 · Tainan, Taiwan
    • Investigator site 8860017 · Taoyuan, Taiwan
    Show 2 removed
    • Investigator site 8860013 · Tainan City, Taiwan
    • Investigator site 8860017 · Taoyuan District, Taiwan
    + 4 other changes: identifiers, verification date, registry dates and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04280718
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Feb 21, 2020
Start date
Sep 18, 2020
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion